𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

✍ Scribed by Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burton; Steven J Ketchel; Charles D Cobau; Ellis G Levine; James N Ingle; Kathleen I Pritchard; Allen S Lichter; Daniel J Schneider; Martin D Abeloff; I Craig Henderson; Hyman B Muss; Stephanie J Green; Danika Lew; Robert B Livingston; Silvana Martino; C Kent Osborne

Book ID
117305425
Publisher
The Lancet
Year
2009
Tongue
English
Weight
145 KB
Volume
374
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase 2 randomized trial of primary endo
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
✍ Vladimir F. Semiglazov; Vladislav V. Semiglazov; Garik A. Dashyan; Elena K. Zilt πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 194 KB

## Abstract ## BACKGROUND. Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative chemotherapy with doxorubicin or taxanes may be reduced in postmenopausal patients with estrogen receptor (ER)‐positive and/